About Scientari

Building a Pharma Intelligence Ecosystem

Scientari’s founder, Christopher Hoover, spent three decades taking complex life-science and deep-tech platforms to market—as the early commercial person who learns a new technology domain fast, he figures out how to position it and builds the infrastructure that turns science into revenue.

The idea is simple: deep, actionable analysis that helps individual practitioners make better strategic decisions without waiting for their organization to commission a report or develop in-house solutions.

Scientari has launched the first of patent-pending pharma intelligence platforms: TrialReadiness helps clinical teams optimize protocols prior to phase 2 expenditure ramp up, and Repothesis is our evidence-based engine for drug repositioning.

We’re also developing a line of strategy guides on topics such as: drug delivery, orphan drug designation, Pre-IND planning, DNA sequencing, omics data resources and workflows, hydrogen production for data centers, and FPGA architecture — each paired with an interactive web app that lets you explore the data, run the analysis, and apply it to your own decisions.

Background

Launching his career with Invitrogen in 1989—then a  20-person startup—he helped it grow into a publicly traded company of 2,700 employees. He built their first full catalog website in the early ’90s—before most life-science companies had a web presence—eventually scaling it to 10,000+ documents, integrated databases, user forums, and one of the industry’s first online gene-clone ordering systems with built-in BLAST homology search.

Since then he’s worked across an unusually wide range of technologies, often bringing them to market for the first time. Across multiple companies he helped commercialize FPGA-accelerated genomics—specialized silicon that brought massive speedups to DNA sequence comparison and analysis (in much the same way GPUs accelerate AI today). Working with purpose-built hardware that outpaced general-purpose CPUs gave him a unique perspective on scientific compute burdens. .

Mr Hoover then led the U.S. launch of MedinCell (Euronext: MEDCL) as CEO of its U.S. subsidiary, building a San Diego formulation lab that ran multi-million-dollar programs; the U.S. operation drove a major share of global revenue, and the platform he helped commercialize went on to yield an FDA-approved product a decade later.

He participated in the launch of a successful digital health platform, worked in animal and digital health (IoT health monitoring and Machine Learning-based video analysis of behavior enriched preclinical data), marketed RFID solutions for anti-counterfeiting and consumer engagement, and worked in the energy sector on plasma-based reforming of natural gas for hydrogen production.

His unique skills have enabled him to quickly adapt to new markets to become the commercial bridge between hard science and the market.

Alongside operating roles, he has made several angel investments in early-stage life-science and deep-tech companies, and has held equity in many ventures he helped build—including several that reached public markets or were acquired.

Channeling this experience into Scientari LLC, we’re building an ecosystem of strategy guides, interactive tools, and decision platforms for professionals in biopharma, genomics, energy technology, and computing.

Explore, Analyze, Decide.